Effects of Gefitinib on Radiation-induced Lung Injury in Mice
Author:
Affiliation:
1. Department of Pulmonary Medicine/Infection and Oncology, Graduate School of Medicine, Nippon Medical School
Publisher
Medical Association of Nippon Medical School
Subject
General Medicine
Link
https://www.jstage.jst.go.jp/article/jnms/75/2/75_2_96/_pdf
Reference22 articles.
1. 1. Fukuoka M, Yano S, Giaccone G, et al.: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2273-2246.
2. 2. Kris MG, Natale RB, Herbst RS, et al.: Efficacy of gefinitib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158.
3. 3. Baselga J: Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: Small molecules, big hope. J Clin Oncol 2002; 20: 2217-2219.
4. 4. Inoue A, Saijyo Y, Maemondo M, et al.: Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361: 137-139.
5. 6. Camus P, Kudoh S, Ebina M: Interstitial lung disease associated with drug therapy. Brtish J Cancer 2004; 91: S18-S23.
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration;Signal Transduction and Targeted Therapy;2022-05-13
2. A Drug Interaction between Crizotinib and Warfarin in Non-Small-Cell Lung Cancer: A Case Report;Journal of Nippon Medical School;2017
3. Transforming Growth Factor Alpha is a Critical Mediator of Radiation Lung Injury;Radiation Research;2014-08-12
4. Biodetection and Biointervention: Cytokine Pathways as a Rationale for Anti-cytokine Interventions Post-Radiation;ALERT - Adverse Late Effects of Cancer Treatment;2013-10-04
5. Fibrosis;Pathobiology of Cancer Regimen-Related Toxicities;2012-12-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3